Skip to content

Abivax

  • EN
  • FR
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
  • EN
  • FR

News & Events

Press Coverage

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019

Les Echos-Investir

May 2, 2020

Abivax grimpe en Bourse après l’accord des autorités allemandes pour poursuivre son étude contre le Covid-19

Empowered Patient Podcast

March 25, 2020

Interview with Hartmut Ehrlich – Novel Anti-Inflammatory Therapeutic Agent Showing Promise for Ulcerative Colitis

BFM Business TV

February 17, 2020

Interview with Philippe Pouletty – Abivax: The company of the day

La Gazette du Laboratoire

February 17, 2020

ABIVAX: a strategic shift for its clinical programs

4 investors

February 13, 2020

Shareholder value will be “crucial criteria” for Evotec-Partner

  • 1
  • …
  • 33
  • 34
  • 35
  • 36
  • 37
  • …
  • 46

References available upon request.

© 2025 All rights reserved by Abivax 07/2024 Privacy and Terms of Use
Consent Preferences
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
Contact Us
  • Follow us on Twitter
  • Follow us on LinkedIn